Published data indicate that the HER2/HER3 signaling pathways play an important role both in NSCLC tumors resistant to inhibitors of EGFR (cetuximab and erlotinib) 78-81 and in NSCLC cancers driven by activating mutations in HER2 (4% of NCSLC patients) 82. The gene discussed is ERBB2; the disease is cancer.